AMENDMENTS TO THE CLAIMS:

Please amend the claims as follows:

Claims 1-10. (Canceled)

11. (Previously Presented) A method of treating arthritis, comprising administering to a patient, as an active ingredient, an antibody which specifically binds to FGF-8 to inhibit activity of FGF-8,

wherein the antibody is a monoclonal antibody selected from an antibody produced by a hybridoma, a humanized antibody and an antigen-binding fragment thereof,

wherein the humanized antibody is a human chimeric antibody or a human complementarity determining region (CDR)-grafted antibody comprising CDRs of VH and VL of a monoclonal antibody which specifically binds to FGF-8 to inhibit activity of FGF-8 and CH and CL of a human antibody,

wherein CDR1, CDR2 and CDR3 of VH comprise amino acid sequences represented by SEQ ID NOS: 7, 8 and 9 respectively and CDR1, CDR2 and CDR3 of VL comprise amino acid sequences represented by SEQ ID NOS: 10, 11 and 12 respectively.

Claim 12. (Canceled)

13. (Previously Presented) A method of treating arthritis, comprising administering to a patient, as an active ingredient, an antibody which specifically binds to FGF-8 to inhibit activity of FGF-8,

wherein the antibody is a monoclonal antibody selected from an antibody produced by a hybridoma, a humanized antibody and an antigen-binding fragment thereof,

wherein the humanized antibody is a human chimeric antibody or a human complementarity determining region (CDR)-grafted antibody comprising CDRs of VH and VL of a monoclonal antibody which specifically binds to FGF-8 to inhibit activity of FGF-8 and CH and CL of a human antibody,

wherein VH comprises an amino acid sequence represented by SEQ ID NO: 18 or 20 and VL comprises an amino acid sequence represented by SEQ ID NO: 19, 21, 42, 43, 44, 45, 46, 47, 50 or 51.

14. (Previously Presented) The method according to claim 13, wherein the human CDR-grafted antibody is any of the following human CDR-grafted antibodies (a) to (c),

(a) a human CDR-grafted antibody in which VH comprises an amino acid sequence represented by SEQ ID NO: 18 and VL comprises an amino acid sequence represented by SEQ ID NO: 21,

(b) a human CDR-grafted antibody in which VH comprises an amino acid sequence represented by SEQ ID NO: 18 and VL comprises an amino acid sequence represented by SEQ ID NO: 44, and

(c) a human CDR-grafted antibody in which VH comprises an amino acid sequence represented by SEQ ID NO: 18 and VL comprises an amino acid sequence represented by SEQ ID NO: 50.

15. (Previously Presented) A method of treating arthritis, comprising administering to a patient, as an active ingredient, an antibody which specifically binds to FGF-8 to inhibit activity of FGF-8,

wherein the antibody is a monoclonal antibody selected from an antibody produced by a hybridoma, a humanized antibody and an antigen-binding fragment thereof,

wherein the humanized antibody is a human chimeric antibody or a human complementarity determining region (CDR)-grafted antibody comprising CDRs of VH and VL of a monoclonal antibody which specifically binds to FGF-8 to inhibit activity of FGF-8 and CH and CL of a human antibody,

wherein the human CDR-grafted antibody is any of the following human CDR-grafted antibodies (a) to (c),

(a) a human CDR-grafted antibody produced by transformant KM8037 (FERM BP-8084),

(b) a human CDR-grafted antibody produced by transformant KM8035 (FERM BP-8082), and

(c) a human CDR-grafted antibody produced by transformant KM8036 (FERM BP-8083).

Claims 16-51. (Canceled)